AdelineMVerticelliMD

Physician

Dr. Verticelli is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Internal Medicine, 1998 - 2002
Georgetown University School of MedicineClass of 1998

PubMed

1 citations
First-in-Human Study for a Selective Rearranged During Transfection Tyrosine Kinase Inhibitor, GSK3352589, to Investigate the Safety, Tolerability, and Pharmacokinetic...
Beth Ann Reedy, Robin O'Connor-Semmes, Kimberley Hacquoil, Peter D. Gorycki, Adeline Verticelli
Clinical Pharmacology in Drug Development. 2021-04-01
2 citations
First-in-Human Studies for a Selective RET Tyrosine Kinase Inhibitor, GSK3179106, to Investigate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers.
Melisa Cooper, Robin O'Connor-Semmes, Beth Ann Reedy, Kimberley Hacquoil, Peter D. Gorycki
Clinical Pharmacology in Drug Development. 2019-02-01
91 citations
Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers.
Kathleen M. Weisel, Nicola Scott, Debra J. Tompson, Bartholomew J. Votta, Sujith Madhavan
Pharmacology Research & Perspectives. 2017-12-01